Italian pharmaceutical company Recordati has reported a net profit
growth of 6.5 per cent to €18.5m in its third quarter results, as a
slump in sales was offset by lower costs.
Qiagen, today announced that it has acquired all outstanding shares
of Genaco Biomedical Products in a deal that adds PCR-based,
multiplexed molecular diagnostics technologies and panels to
Qiagen's portfolio.
A start-up company has given new hope for patients with brain
tumour by developing a new medical device that it claims is the
first ultrasound-based system to allow drug delivery to the brain.
UK-based Synexus Clinical Research is continuing its global
movements with the latest acquisition of South African outfit
Clinical Research Centers (CRC).
Scientists have mapped the entire genetic sequence of breast and
colon cancers, which could lead to better ways to diagnose cancer
in its early, most treatable stages, as well as further develop
personalised treatments.
A white paper that looks at the eClinical business model strategies
has concluded that larger investments and access to multicomponent,
single-source contracting options will create more efficient models
for businesses.
BioWa has announced it is to commence Phase 1 clinical trials
anti-IL-5 receptor monoclonal antibody (Mab), which is being
developed for the treatment of asthma, a respiratory disorder that
is on the rise, particularly in children.
The US Food and Drug Administration (FDA) has announced the launch
of a new guidance to help drug makers evaluate lab test results
that fall outside the specification limits.
The contract packaging biz is moving from an ad-hoc to a more
strategically determined, long-term approach, as pharma companies
begin to relax in the arms of service providers.
A year after it published its five-year strategy: Vision 2010 -
Building on Strengths - DSM's commitment is showing no sign of
slowing as is continues to invest in the expansion of its
pharmaceutical production capabilities around...
Gerresheimer has announced it will launch a new plastic syringe
range in January to cater for highly-sensitive medications and also
for high-volume injections.
Scientists have uncovered a naturally occurring enzyme that can
break down a component of the brain plaques that play a central
role in Alzheimer's disease, which could provide researchers with a
basis for new therapies to treat...
The next generation of anti-cancer drugs took a positive step
forward after scientists successfully inhibited an enzyme that is
responsible for catalysing uncontrolled and abnormal cell
divisions.
US-based drug maker Cleveland BioLabs has teamed up with
biopharmaceutical manufacturer Synco Bio Partners to produce its
leading radioprotection molecule for clinical trials and
commercialisation
Thermo Electron has continued to show strong growth in the third
quarter 2006 buoyed on by strong returns in its mass spectrometry
business and progress in its Triple Quad technology.
The Massachusetts Institute of Technology (MIT) has designed a
portable "lab on a chip" diagnostic device, which the researchers
say could identify biological or chemical weapons faster and easier
than current methods.
Pharmaceutical companies are beginning to catch up with other
industry sectors that take an increasingly realistic view of what
they consider a core competency and outsourcing what is left -
Outsourcing-Pharma takes a snapshot of...
British-based analysis services provider Intertek ASG has announced
it is expanding its analytical services to meet the growing demand
for macromolecule characterisation.
Fresh from Thermo's $10.4bn (€8.3bn) acquisition of the scientific
equipment and instrument specialists, Fisher Scientific posted
strong third quarter results that showed a profit rise of 62 per
cent coupled with an 11 per cent...
Although manufacturing is the most established of the pharma
outsourcing segments, many service areas are still rapidly
evolving. OutsourcingPharma.com gives a brief run down of the
current state of play.
Curalogic, a Danish biotechnology company, has appointed SAFC's
Pharma business segment to provide protein isolation, extraction
and purification services as part of its product development to
treat Allergic Rhinitis.
Charles River Laboratories has been awarded a $111.6m (€89m),
10-year contract from the National Cancer Institute (NCI), doubling
the size of the company's current contract with NCI.
According to a new study the European cardiovascular drugs market
is expected to reach $36.3bn (€28.9bn) in 2012, buoyed on by new
drug areas, classes and combination products.
Pharma companies that aren't maximising their outsourcing potential
in clinical research may be wasting a world of opportunity.
OutsourcingPharma.com gives a brief run down of exactly what kinds
of services and providers are...
Drug maker Eli Lilly has completed the first phase of a $560m
(€446m) expansion of its biotech facility in Indianapolis, US, in
order to match the growing number of biological drugs in its
pipeline.
GlaxoSmithKline (GSK) has indicated it will rely more heavily on
Asian R&D in the future and has already been stepping up its
involvement in India and Singapore.
As the Asia-Pacific continues to be a hotspot for clinical trials
activity, e-clinical provider ClinPhone has opened its first office
in the region in the hope of gaining a head start.
The Food and Drug Administration (FDA) is expected to issue a
revised version of its regulation on electronic signatures and
records by the end of the year, which will force drug and device
companies to reconsider their current information...
Findings from new study have offered an innovative profile of an
enzyme that aids tumour growth, which points towards a potential
new target for treatments for ovarian and breast cancers.
A new dry powder inhaler that may cost less than a syringe and
deliver 40 per cent more active drug than current inhalers has been
unveiled by its maker, Cambridge Consultants.
Researchers have developed a biochip that could prove crucial in
future drug development. The technology measures electrical
activities of cells and can obtain 60 times more data in one
reading than is possible with current technology.
PPD managed a net revenue of $313.1m (€250m) for the third quarter
of 2006, an increase of 14.6 per cent over net revenue of $273.3m
for the third quarter of 2005. This has been buoyed on by the
strong performance by the company's...
Developing new drugs represents an enormous expense for pharma
companies with top firms spending up to £4bn (€6bn) a year on
R&D, according to new industry report.
Using a modified version of nuclear magnetic resonance technology,
(NMR) scientists have revealed the therapeutic potential of an
insect's venom, which could be utilised to provide a better
understanding of Alzheimer's disease...
For pharma companies that are hesitant about outsourcing during the
drug discovery stage, a world of opportunity awaits.
OutsourcingPharma.com gives a brief run down of what kinds of
services are on offer, as well as a few potential...
Eli Lilly has splashed out $2.1bn (€1.7bn) to buy ICOS, who the
drug giant has been involved in a joint venture with to manufacture
and sell Cialis (tadalafil) - the number two erectile dysfunction
drug behind Viagra (sildenafil).
Minimising the risk of cross-contamination in the production of
medicines for use in clinical trials is a major challenge for
manufacturers, who need to implement safety measures in order to
avoid production failure.
China is a big market with a lot of potential but many pharma
industry firms still avoid doing business in the country because of
fears that their intellectual property (IP) cannot be protected.
Fewer first cycle new drug approvals by the US Food and Drug
Administration (FDA) could be the first evidence of a toughening
regulatory environment, according to new research.
Mettler Toledo has introduced its new range of titrators, which have been specifically designed for repeated routine analyses focusing on time efficiency and fast results that are crucial components of a clinical drug trial.